A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
